Donnez J, Nisolle-Pochet M, Casanas-Roux F
Department of Gynaecology, University of Louvain, Cliniques Universitaires St. Luc, Brussels, Belgium.
Int J Fertil. 1990 Sep-Oct;35(5):297-301.
In order to assess adequately the effectiveness of danazol, Gestrinone, and Buserelin, a prospective nonrandomized study was initiated in 126 patients with laparoscopically confirmed ovarian endometriosis. After hormonal therapy, laparotomy with microsurgical resection of endometriotic cysts was carried out. Regression (greater than 25%) of ovarian endometriosis was noted in 30%, 34%, and 73% of cases after danazol, Gestrinone, and Buserelin, respectively. The pregnancy rate in moderate endometriosis (53%) differed significantly from the rate obtained in severe endometriosis (45%). The highest percentages were found after Buserelin therapy. In conclusion, Buserelin emerged superior to danazol or Gestrinone treatment. Nevertheless, hormonal treatment leads to an incomplete suppression of ovarian endometriotic implants and this suggests the necessity of surgically removing invasive ovarian endometriosis.
为了充分评估达那唑、孕三烯酮和布舍瑞林的疗效，对126例经腹腔镜确诊为卵巢子宫内膜异位症的患者开展了一项前瞻性非随机研究。激素治疗后，进行剖腹手术并显微切除子宫内膜异位囊肿。达那唑、孕三烯酮和布舍瑞林治疗后，分别有30%、34%和73%的病例出现卵巢子宫内膜异位症消退（大于25%）。中度子宫内膜异位症的妊娠率（53%）与重度子宫内膜异位症的妊娠率（45%）有显著差异。布舍瑞林治疗后的妊娠率最高。总之，布舍瑞林治疗效果优于达那唑或孕三烯酮。然而，激素治疗会导致卵巢子宫内膜异位植入物不能完全被抑制，这表明手术切除侵袭性卵巢子宫内膜异位症的必要性。
